wow jili login

wow jili login LKQ Co. (NASDAQ:LKQ) Given Consensus Recommendation of “Buy” by BrokeragesSet up in 2020, SEBCC’s fate uncertain after Dec 17; extension unlikelySondra Williams announced on Instagram on Sunday that she gave birth to Trenton O’Brien Williams Jr. on Nov. 24. Williams also wrote that she was initially pregnant with twins and lost the other child earlier in the pregnancy. “I can’t even begin to describe how I felt leaving the hospital without you,” she wrote. “Nor how it feels being home celebrating Thanksgiving without my baby in my arms. My heart is broken and my arms are empty. But I know you’ll always be near watching over me and your sisters. And for that, my heart smiles with gratitude. Thank God for allowing us to bond for 35 weeks and for me to birth you so I could hold you in my arms. I’m at peace knowing you will never have to suffer.” Williams wrote that her son was diagnosed with Trisomy 13, a genetic condition also known as Patau syndrome that affects how the face, brain and heart develop, along with several other internal organs. Trent Williams spent time last week at the hospital and grieving with his family, including the couple's three young daughters. “He was there at the hospital with her and got to meet him and say bye,” coach Kyle Shanahan said Monday. "Then he had to cremate him on Friday. So he’s been dealing with that and he’s working through it. But we’re all just trying to be here for him through it all.” This is the second tragedy to hit the Niners in recent weeks. Cornerback Charvarius Ward's 1-year-old daughter , Amani Joy, died on Oct. 28. She had born prematurely with Down syndrome and had open-heart surgery in April 2023. Ward spent a few weeks away from the team and returned to the field for the first time on Sunday. Williams has missed the last two games with an ankle injury but Shanahan said he is hoping to be able to the return as soon as he's healthy. “It’s hard as a coach. It’s hard as a friend. It’s hard as a family member. It’s hard for everybody," Shanahan said. ”But we spend a lot of time with each other. That’s what’s cool about a football team. Whatever you go through, the good or the bad, we go through it together. I do like that they have a group of guys they can go to, a group of guys that can see them every day. You can never escape that full grief and stuff. But I do think it’s nice for those guys to have another avenue to get out on the football field, to get around teammates and things like that." AP NFL: https://apnews.com/hub/nfl

Richard C. Young & CO. LTD. boosted its position in Amazon.com, Inc. ( NASDAQ:AMZN – Free Report ) by 2.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,746 shares of the e-commerce giant’s stock after buying an additional 2,052 shares during the quarter. Amazon.com makes up about 1.8% of Richard C. Young & CO. LTD.’s investment portfolio, making the stock its 21st biggest holding. Richard C. Young & CO. LTD.’s holdings in Amazon.com were worth $16,350,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also recently bought and sold shares of the company. PayPay Securities Corp boosted its holdings in Amazon.com by 64.6% in the second quarter. PayPay Securities Corp now owns 163 shares of the e-commerce giant’s stock worth $32,000 after purchasing an additional 64 shares during the period. Hoese & Co LLP acquired a new position in shares of Amazon.com in the 3rd quarter valued at about $37,000. Bull Oak Capital LLC acquired a new position in shares of Amazon.com in the 3rd quarter valued at about $45,000. Christopher J. Hasenberg Inc grew its position in shares of Amazon.com by 650.0% during the 2nd quarter. Christopher J. Hasenberg Inc now owns 300 shares of the e-commerce giant’s stock valued at $58,000 after buying an additional 260 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Amazon.com during the third quarter worth about $56,000. Institutional investors and hedge funds own 72.20% of the company’s stock. Analyst Upgrades and Downgrades AMZN has been the topic of several analyst reports. DA Davidson reaffirmed a “buy” rating and issued a $235.00 target price on shares of Amazon.com in a research report on Thursday, October 10th. The Goldman Sachs Group increased their price objective on shares of Amazon.com from $230.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Evercore ISI boosted their target price on shares of Amazon.com from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lifted their price target on Amazon.com from $225.00 to $232.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada increased their price objective on Amazon.com from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Two analysts have rated the stock with a hold rating, forty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Amazon.com has an average rating of “Moderate Buy” and an average price target of $243.00. Insider Activity In other Amazon.com news, CEO Douglas J. Herrington sold 3,500 shares of Amazon.com stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $210.00, for a total transaction of $735,000.00. Following the transaction, the chief executive officer now directly owns 524,567 shares of the company’s stock, valued at approximately $110,159,070. The trade was a 0.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Also, Director Jonathan Rubinstein sold 5,004 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $199.85, for a total transaction of $1,000,049.40. Following the sale, the director now owns 99,396 shares of the company’s stock, valued at approximately $19,864,290.60. This trade represents a 4.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last ninety days, insiders sold 6,032,344 shares of company stock worth $1,253,456,822. Insiders own 10.80% of the company’s stock. Amazon.com Stock Performance Shares of NASDAQ:AMZN opened at $223.75 on Friday. Amazon.com, Inc. has a 12-month low of $144.05 and a 12-month high of $233.00. The company’s 50 day moving average price is $209.73 and its two-hundred day moving average price is $192.85. The firm has a market cap of $2.35 trillion, a PE ratio of 47.91, a PEG ratio of 1.54 and a beta of 1.16. The company has a quick ratio of 0.87, a current ratio of 1.09 and a debt-to-equity ratio of 0.21. Amazon.com ( NASDAQ:AMZN – Get Free Report ) last posted its quarterly earnings results on Thursday, October 31st. The e-commerce giant reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.29. The company had revenue of $158.88 billion during the quarter, compared to analysts’ expectations of $157.28 billion. Amazon.com had a return on equity of 22.41% and a net margin of 8.04%. Amazon.com’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 EPS. Equities research analysts predict that Amazon.com, Inc. will post 5.29 earnings per share for the current year. Amazon.com Profile ( Free Report ) Amazon.com, Inc engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. See Also Five stocks we like better than Amazon.com Transportation Stocks Investing Buffett Takes the Bait; Berkshire Buys More Oxy in December How Can Retail Investors Trade the Toronto Stock Exchange (TSX)? Top 3 ETFs to Hedge Against Inflation in 2025 Trading Halts Explained These 3 Chip Stock Kings Are Still Buys for 2025 Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter .N44bn accrued benefits: Group slams FG over uncovered retirees’ fate

Cetera Strengthens Executive Leadership to Propel Strategic Growth and InnovationAncient meets modern as a new subway in Greece showcases archaeological treasures THESSALONIKI, Greece (AP) — Thessaloniki, Greece’s second-largest city, is opening a new subway system, blending ancient archaeological treasures with modern transit technology like driverless trains and platform screen doors. The project, which began in 2003, uncovered over 300,000 artifacts, including a Roman-era thoroughfare and Byzantine relics, many of which are now displayed in its 13 stations. Despite delays caused by preserving these findings, the inaugural line has been completed, with a second line set to open next year. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. At least 19 people are sick in Minnesota from ground beef tied to E. coli recall U.S. health officials say at least 19 people in Minnesota have been sickened by E. coli poisoning tied to a national recall of more than 167,000 pounds of potentially tainted ground beef. Detroit-based Wolverine Packing Co. recalled the meat this week after Minnesota state agriculture officials reported multiple illnesses and found that a sample of the product tested positive for E. coli O157:H7, which can cause life-threatening infections. Symptoms of E. coli poisoning include fever, vomiting, diarrhea and signs of dehydration. Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. Actor Jonathan Majors’ ex-girlfriend drops assault and defamation lawsuit against once-rising star NEW YORK (AP) — Jonathan Majors’ ex-girlfriend has dropped her assault and defamation lawsuit against the once-rising Hollywood star after reaching a settlement. Lawyers for Majors and Grace Jabbari agreed to dismiss the case with prejudice Thursday. Jabbari is a British dancer who had accused Majors of subjecting her to escalating incidents of physical and verbal abuse during their relationship. Representatives for Majors didn’t respond to emails seeking comment Friday. Jabbari’s lawyer said the suit was “favorably settled” and her client is moving on with “her head held high.” Majors was convicted of misdemeanor assault and harassment last December and sentenced to a yearlong counseling program. Hyundai, Kia recall over 208,000 electric vehicles to fix problem that can cause loss of power DETROIT (AP) — Hyundai and Kia are recalling over 208,000 electric vehicles to fix a pesky problem that can cause loss of drive power, increasing the risk of a crash. The recalls cover more than 145,000 Hyundai and Genesis vehicles including the 2022 through 2024 Ioniq 5, the 2023 through 2025 Ioniq 6, GV60 and GV70, and the 2023 and 2024 G80. Also included are nearly 63,000 Kia EV 6 vehicles from 2022 through 2024. The affiliated Korean automakers say in government documents that a transistor in a charging control unit can be damaged and stop charging the 12-volt battery. Dealers will inspect and replace the control unit and a fuse if needed. They also will update software. Christmas TV movies are in their Taylor Swift era, with two Swift-inspired films airing this year Two of the new holiday movies coming to TV this season have a Taylor Swift connection that her fans would have no problem decoding. “Christmas in the Spotlight” debuts Saturday on Lifetime. It stars Jessica Lord as the world’s biggest pop star and Laith Wallschleger, playing a pro football player, who meet and fall in love, not unlike Swift and her boyfriend, Kansas City Chiefs tight end Travis Kelce. On Nov. 30, Hallmark will air “Holiday Touchdown: A Chiefs Love Story.” Instead of a nod to Swift, it’s an ode to family traditions and bonding, like rooting for a sports team. Hallmark’s headquarters is also in Kansas City. Top football recruit Bryce Underwood changes commitment to Michigan instead of LSU, AP source says ANN ARBOR, Mich. (AP) — Top football recruit Bryce Underwood has flipped to Michigan after pledging to play at LSU. That's according to a person familiar with the situation who spoke to The Associated Press on condition of anonymity because they were not authorized to share the recruit’s plans to join the Wolverines. Underwood pinned a post on his Instagram account, showing a post in which On3.com reported that he has committed to Michigan. The 6-foot-3 quarterback played at Belleville High School about 15 miles east of Michigan's campus, and told LSU nearly a year ago he intended to enroll there. Emperor penguin released at sea 20 days after waddling onto Australian beach MELBOURNE, Australia (AP) — The only emperor penguin known to have swum from Antarctica to Australia has been released at sea 20 days after he waddled ashore on a popular tourist beach. The adult male was found on Nov. 1 on sand dunes in temperate southwest Australia about 2,200 miles north of the Antarctic coast. He was released Wednesday from a boat that traveled several hours from Western Australia state's most southerly city of Albany. His caregiver Carol Biddulph wasn't sure at first if the penguin would live. She said a mirror was important to his rehabilitation because they provide a sense of company. Biddulph said: “They’re social birds and he stands next to the mirror most of the time.” Shohei Ohtani wins third MVP award, first in NL. Aaron Judge earns second AL honor in 3 seasons NEW YORK (AP) — Shohei Ohtani won his third Most Valuable Player Award and first in the National League, and Aaron Judge earned his second American League honor on Thursday. Ohtani was a unanimous MVP for the third time, receiving all 30 first-place votes and 420 points in voting by the Baseball Writers’ Association of America. New York Mets shortstop Francisco Lindor was second with 263 points and Arizona second baseman Ketel Marte third with 229. Judge was a unanimous pick for the first time. Kansas City shortstop Bobby Witt Jr. got all 30 second-place votes for 270 points, and Yankees outfielder Juan Soto was third with 21 third-place votes and 229 points.

Spartan Capital Securities is Pleased to Announce the Hiring of Vito Coviello, Chief Financial ...

Qatar PM Sees 'Momentum' On Gaza Talks After US ElectionTEL AVIV, Israel (AP) — Israeli Prime Minister Benjamin Netanyahu underwent successful surgery Sunday to have his prostate removed, hospital officials said, a procedure that came as he manages multiple crises including the war in Gaza and his trial for alleged corruption . Netanyahu, who has had a series of health issues in recent years, has gone to great lengths to bolster a public image of himself as a healthy, energetic leader. During his trial this month, he boasted about working 18-hour days, accompanied by a cigar. But as Israel's longest-serving leader, such a grueling workload over a total of 17 years in power could take a toll on his well-being. Netanyahu, 75, is among older world leaders including U.S. President Joe Biden, 82 , President-elect Donald Trump, 78 , Brazil's President Luiz Inácio Lula da Silva , 79, and Pope Francis , 88, who have come under scrutiny for their age and health issues. Netanyahu's latest condition is common in older men, but the procedure has had some fallout. The judges overseeing his trial accepted a request from his lawyer on Sunday to call off three days of testimony scheduled this week. The lawyer, Amit Hadad, had argued that Netanyahu would be fully sedated for the procedure and hospitalized for “a number of days.” Jerusalem's Hadassah Medical Center announced late Sunday that the procedure had been “completed successfully.” Justice Minister Yariv Levin, a close ally, served as acting prime minister during the operation. Netanyahu is expected to remain hospitalized for several days. With so much at stake, Netanyahu’s health in wartime is a concern for both Israelis and the wider world. As Israel’s leader, Netanyahu is at the center of major global events that are shifting the Middle East . With the dizzying pace of the past 14 months, being incapacitated for even a few hours can be risky. Netanyahu will be in the hospital at a time when international mediators are pushing Israel and Hamas to reach a ceasefire in Gaza and as fighting between Israel and Yemen’s Iran-backed Houthi rebels intensifies . Prostate issues are common and in many cases easily treatable. Still, the procedure puts a dent in Netanyahu’s image of vigor at a time when he would want to project strength more than ever, both to an Israeli audience navigating constant threats as well as to Israel’s enemies looking to expose its weaknesses. Netanyahu insists he is in excellent health. His office releases footage of him touring war zones in full protective gear flanked by military officers, or meeting with defense officials on windswept hilltops in youthful dark shades and puffer jackets. But that image was shattered last year when Netanyahu’s doctors revealed that he had a heart condition , a problem that he had apparently long known about but concealed from the public. A week after a fainting spell, Netanyahu was fitted with a pacemaker to control his heartbeat. Only then did staff at the Sheba Medical Center reveal that Netanyahu has for years experienced a condition that can cause irregular heartbeats. The revelation came as Netanyahu was dealing with massive anti-government protests. The news about a chronic heart problem stoked further anger and distrust during extreme political polarization in Israel. Last year, Netanyahu was rushed to the hospital for what doctors said likely was dehydration . He stayed overnight, prompting his weekly Cabinet meeting to be delayed. Earlier this year, Netanyahu underwent hernia surgery , during which he was under full anesthesia and unconscious. Levin served as acting prime minister during the operation. According to Netanyahu’s office, the Israeli leader was diagnosed with a urinary tract infection on Wednesday stemming from a benign enlargement of his prostate. The infection was treated successfully with antibiotics, but doctors said the surgery was needed in any case. Complications from prostate enlargement are common in men in their 70s and 80s, Dr. Shay Golan, head of the oncology urology service at Israel’s Rabin Medical Center, told Israeli Army Radio. Golan spoke in general terms and was not involved in Netanyahu’s care or treatment. He said an enlarged prostate can block proper emptying of the bladder, leading to a build-up of urine that can lead to an infection or other complications. After medicinal treatment, doctors can recommend a procedure to remove the prostate to prevent future blockages, Golan said. In Netanyahu’s case, because the prostate is not cancerous, Golan said doctors were likely performing an endoscopic surgery, carried out by inserting small instruments into a body cavity, rather than making surgical cuts in the abdomen to reach the prostate. The procedure lasts about an hour, Golan said, and recovery is quick. He said that aside from catheter use for one to three days after the procedure, patients can return to normal activity without significant limitations. AP correspondent Isaac Scharf contributed reporting.

Killing of UnitedHealthcare CEO spotlights complex challenge companies face in protecting top brass

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease ("MGD") Showing Cost Savings Over Existing Reimbursed Treatment OptionsWhat happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-CowboysA hamstring injury silenced George Pickens. His Steelers teammates picked up the slack vs. Browns

Wade Taylor IV helps No. 13 Texas A&M rout Abilene ChristianRichard C. Young & CO. LTD. boosted its position in Amazon.com, Inc. ( NASDAQ:AMZN – Free Report ) by 2.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,746 shares of the e-commerce giant’s stock after buying an additional 2,052 shares during the quarter. Amazon.com makes up about 1.8% of Richard C. Young & CO. LTD.’s investment portfolio, making the stock its 21st biggest holding. Richard C. Young & CO. LTD.’s holdings in Amazon.com were worth $16,350,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also recently bought and sold shares of the company. PayPay Securities Corp boosted its holdings in Amazon.com by 64.6% in the second quarter. PayPay Securities Corp now owns 163 shares of the e-commerce giant’s stock worth $32,000 after purchasing an additional 64 shares during the period. Hoese & Co LLP acquired a new position in shares of Amazon.com in the 3rd quarter valued at about $37,000. Bull Oak Capital LLC acquired a new position in shares of Amazon.com in the 3rd quarter valued at about $45,000. Christopher J. Hasenberg Inc grew its position in shares of Amazon.com by 650.0% during the 2nd quarter. Christopher J. Hasenberg Inc now owns 300 shares of the e-commerce giant’s stock valued at $58,000 after buying an additional 260 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Amazon.com during the third quarter worth about $56,000. Institutional investors and hedge funds own 72.20% of the company’s stock. Analyst Upgrades and Downgrades AMZN has been the topic of several analyst reports. DA Davidson reaffirmed a “buy” rating and issued a $235.00 target price on shares of Amazon.com in a research report on Thursday, October 10th. The Goldman Sachs Group increased their price objective on shares of Amazon.com from $230.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Evercore ISI boosted their target price on shares of Amazon.com from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lifted their price target on Amazon.com from $225.00 to $232.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada increased their price objective on Amazon.com from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Two analysts have rated the stock with a hold rating, forty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Amazon.com has an average rating of “Moderate Buy” and an average price target of $243.00. Insider Activity In other Amazon.com news, CEO Douglas J. Herrington sold 3,500 shares of Amazon.com stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $210.00, for a total transaction of $735,000.00. Following the transaction, the chief executive officer now directly owns 524,567 shares of the company’s stock, valued at approximately $110,159,070. The trade was a 0.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Also, Director Jonathan Rubinstein sold 5,004 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $199.85, for a total transaction of $1,000,049.40. Following the sale, the director now owns 99,396 shares of the company’s stock, valued at approximately $19,864,290.60. This trade represents a 4.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last ninety days, insiders sold 6,032,344 shares of company stock worth $1,253,456,822. Insiders own 10.80% of the company’s stock. Amazon.com Stock Performance Shares of NASDAQ:AMZN opened at $223.75 on Friday. Amazon.com, Inc. has a 12-month low of $144.05 and a 12-month high of $233.00. The company’s 50 day moving average price is $209.73 and its two-hundred day moving average price is $192.85. The firm has a market cap of $2.35 trillion, a PE ratio of 47.91, a PEG ratio of 1.54 and a beta of 1.16. The company has a quick ratio of 0.87, a current ratio of 1.09 and a debt-to-equity ratio of 0.21. Amazon.com ( NASDAQ:AMZN – Get Free Report ) last posted its quarterly earnings results on Thursday, October 31st. The e-commerce giant reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.29. The company had revenue of $158.88 billion during the quarter, compared to analysts’ expectations of $157.28 billion. Amazon.com had a return on equity of 22.41% and a net margin of 8.04%. Amazon.com’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 EPS. Equities research analysts predict that Amazon.com, Inc. will post 5.29 earnings per share for the current year. Amazon.com Profile ( Free Report ) Amazon.com, Inc engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. See Also Five stocks we like better than Amazon.com Transportation Stocks Investing Buffett Takes the Bait; Berkshire Buys More Oxy in December How Can Retail Investors Trade the Toronto Stock Exchange (TSX)? Top 3 ETFs to Hedge Against Inflation in 2025 Trading Halts Explained These 3 Chip Stock Kings Are Still Buys for 2025 Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter .

Crosby ‘Palace’ turns 50: Celebrating a half-century of basketball legacy

CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.

On Saturday, December 7, heads of state and policymakers as well as business leaders convene in Qatar for the 22nd edition of the Doha Forum, bannered under “The Innovation Imperative” and coupled with the thematic of diplomacy, dialogue and diversity. As a professor of international politics, I do recognise that the progress of our human race in this 21st century faces unprecedented challenges that threaten the stability of societies and the integrity of the global system. Climate change, intensifying security threats, and the fragility of international order are no longer isolated issues; they are deeply interconnected, compounding one another in ways that demand innovative solutions. To address these challenges effectively, I underline that world leaders would need to foster environments conducive to bold experimentation, embrace inclusive co-operation, and create policies that strike a balance between adaptability and governance stability. The need for innovation in problem-solving Traditional mechanisms of international co-operation, rooted in post-World War II institutions, often falter in the face of contemporary challenges. The complexity of modern problems — ranging from transboundary climate impacts to cybersecurity threats — requires more agile, creative, and cross-sectoral approaches. Innovation, therefore, is not merely an option but a necessity. The desired state of innovation must transcend technological solutions. While advancements in renewable energy technologies, artificial intelligence, and biotechnology are crucial, they alone cannot address nor attempt to solve the structural and systemic challenges underpinning global issues. I believe that innovation lies in rethinking governance models, fostering cross-sector collaboration, and integrating diverse for voices and talents, especially from marginalised communities, into decision-making processes. Key innovation concepts for leaders To rise to the occasion, policymakers and business leaders should prioritise the following innovation concepts: Systemic thinking and foresight Policymakers and business leaders must embrace systems thinking to understand how challenges interconnect across sectors. For instance, climate change exacerbates migration patterns, which in turn strain geopolitical relations. By employing foresight tools including scenario planning and predictive modelling, decision-making process can anticipate cascading effects and design preemptive solutions. Inclusive and collaborative governance Solving global challenges requires input from diverse stakeholders, including governments, private sectors, civil society, and academia. Public-private partnerships can accelerate the implementation of sustainable infrastructure, while local communities must be empowered to contribute to decisions affecting their futures. Experimental policy labs Creating spaces for policy experimentation — where new ideas can be tested at smaller scales — can reduce the risk of large-scale failures. For example, urban areas could serve as testing grounds for smart-city innovations or low-carbon transportation systems, allowing successes to scale globally. Resilience through redundancy In a world of uncertainty, policies must account for multiple contingencies. Redundancy in critical systems — such as energy grids or supply chains — enhances resilience against unforeseen disruptions, whether from natural disasters or geopolitical crises. Digital diplomacy and technology for peacebuilding As technology reshapes geopolitics, digital diplomacy tools can foster dialogue and mediate conflicts. Blockchain, for instance, could enhance transparency in aid distribution, while artificial intelligence might predict flashpoints in security and enable preemptive interventions. Building an innovation-conducive policy environment Innovative problem-solving does not emerge in a vacuum; it requires deliberate policy frameworks to thrive. Policymakers and business leaders must focus on creating environments that nurture experimentation while safeguarding governance and societal stability. The following policy streams should be prioritised: Investing in education and lifelong learning As an academic and an educator, myself, I fundamentally believe that education systems must pivot from rote learning to nurturing critical thinking, creativity, and interdisciplinary knowledge. Skills in areas such as climate science, technology ethics, and conflict resolution are essential for equipping future leaders to address global challenges innovatively. Strengthening multilateral institutions for flexibility Existing multilateral frameworks, such as the United Nations, must evolve to become more flexible and responsive. The latter involves creating specialised task forces or regional coalitions that can address emergent crises more effectively. Establishing risk-tolerant funding mechanisms Governments and international organisations should allocate funds for high-risk, high-reward projects. Lessons from the private sector, such as venture capital models, could inspire public funding mechanisms that support bold experimentation without penalising failure. Encouraging regulatory sandboxes To balance innovation and regulation, policymakers can establish “regulatory sandboxes” in which new technologies or policy ideas are tested under relaxed regulations. For instance, renewable energy startups could operate under tailored frameworks to refine their models before scaling up. Safeguarding equity and inclusion Innovation cannot come at the expense of equity. Policymakers must prioritise distributive justice, ensuring that vulnerable populations are not disproportionately burdened by experimental policies. Climate adaptation strategies, for example, must consider the needs of low-income communities on the frontlines of climate impacts. Enhancing data sharing and transparency A cornerstone of effective innovation is access to reliable data. International agreements on data-sharing protocols — particularly for climate science and public health — can accelerate collective learning and solution development. Balancing innovation and governanceA central tension in fostering innovation is the balance between encouraging experimentation and maintaining governance stability. While bold ideas are needed, they must not come at the cost of societal safety or trust in institutions. The latter requires: Ethical guidelines for innovation Establishing ethical standards ensures that innovations, particularly in emerging technologies including AI or gene editing, align with societal values and prioritise safety. Responsive governance models: Adaptive governance, where policies evolve based on real-time feedback, allows for flexibility without undermining stability. Examples include updating climate agreements to reflect advancements in carbon capture technologies. Engaging citizens: Public trust is foundational to governance stability. Governments should engage citizens in policymaking processes through participatory platforms, enhancing transparency and accountability. Related Story Amir participates in Riyadh Gulf-China Summit for Co-operation and Development Forging the path forward Global challenges will only intensify in the coming decades, but they also present opportunities for transformative progress. By prioritising systemic thinking, inclusivity, and bold experimentation, policymakers and business leaders can lay the groundwork for solutions that transcend immediate crises and address root causes. Policies that enable an innovation-conducive environment — while ensuring equity, stability, and safety — are not just desirable but essential for a sustainable future. Innovation must be reimagined not as a singular breakthrough but as a continuous, collaborative process. Through sustained investment in education, institutional reform, and inclusive policy design, the world can transition from reactive crisis management to proactive problem-solving. The stakes are high, but with urgency and co-operation, humanity has the capacity to navigate these challenges and emerge stronger. The author is an Associate Professor of International Relations and Diplomacy, the co-founder and chairman, American Center for Strategic and International Affairs, and an Abshire-Inamori International Fellow. Social media platforms @khalid.aljufairi (instagram) and @khalidaljufairi (X platform)KYIV, Ukraine — NATO and Ukraine will hold emergency talks Tuesday after Russia attacked a central city with an experimental, hypersonic ballistic missile. escalating the nearly 33-month-old war. The conflict is “entering a decisive phase,” Poland’s Prime Minister Donald Tusk said Friday, and “taking on very dramatic dimensions.” Ukraine’s parliament canceled a session as security was tightened following Thursday’s Russian strike on a military facility in the city of Dnipro. In a stark warning to the West, President Vladimir Putin said in a nationally televised speech the attack with the intermediate-range Oreshnik missile was in retaliation for Kyiv’s use of U.S. and British longer-range missiles capable of striking deeper into Russian territory. Russian President Vladimir Putin speaks Friday during a meeting with the leadership of the Russian Ministry of Defense, representatives of the military-industrial complex and developers of missile systems at the Kremlin in Moscow. Putin said Western air defense systems would be powerless to stop the new missile. Ukrainian military officials said the missile that hit Dnipro reached a speed of Mach 11 and carried six nonnuclear warheads, each releasing six submunitions. Speaking Friday to military and weapons industries officials, Putin said Russia will launch production of the Oreshnik. “No one in the world has such weapons,” he said. “Sooner or later, other leading countries will also get them. We are aware that they are under development. “We have this system now,” he added. “And this is important.” Putin said that while it isn’t an intercontinental missile, it’s so powerful that the use of several of them fitted with conventional warheads in one attack could be as devastating as a strike with strategic — or nuclear — weapons. Gen. Sergei Karakayev, head of Russia’s Strategic Missile Forces, said the Oreshnik could reach targets across Europe and be fitted with nuclear or conventional warheads, echoing Putin’s claim that even with conventional warheads, “the massive use of the weapon would be comparable in effect to the use of nuclear weapons.” In this photo taken from a video released Friday, a Russian serviceman operates at an undisclosed location in Ukraine. Kremlin spokesman Dmitry Peskov kept up Russia's bellicose tone on Friday, blaming “the reckless decisions and actions of Western countries” in supplying weapons to Ukraine to strike Russia. "The Russian side has clearly demonstrated its capabilities, and the contours of further retaliatory actions in the event that our concerns were not taken into account have also been quite clearly outlined," he said. Hungarian Prime Minister Viktor Orbán, widely seen as having the warmest relations with the Kremlin in the European Union, echoed Moscow’s talking points, suggesting the use of U.S.-supplied weapons in Ukraine likely requires direct American involvement. “These are rockets that are fired and then guided to a target via an electronic system, which requires the world’s most advanced technology and satellite communications capability,” Orbán said on state radio. “There is a strong assumption ... that these missiles cannot be guided without the assistance of American personnel.” Orbán cautioned against underestimating Russia’s responses, emphasizing that the country’s recent modifications to its nuclear deployment doctrine should not be dismissed as a “bluff.” “It’s not a trick ... there will be consequences,” he said. Czech Republic's Foreign Minister Jan Lipavsky speaks to journalists Friday during a joint news conference with Ukraine's Foreign Minister Andriiy Sybiha in Kyiv, Ukraine. Separately in Kyiv, Czech Foreign Minister Jan Lipavský called Thursday’s missile strike an “escalatory step and an attempt of the Russian dictator to scare the population of Ukraine and to scare the population of Europe.” At a news conference with Ukrainian Foreign Minister Andrii Sybiha, Lipavský also expressed his full support for delivering the necessary additional air defense systems to protect Ukrainian civilians from the “heinous attacks.” He said the Czech Republic will impose no limits on the use of its weapons and equipment given to Ukraine. Three lawmakers from Ukraine's parliament, the Verkhovna Rada, confirmed that Friday's previously scheduled session was called off due to the ongoing threat of Russian missiles targeting government buildings in central Kyiv. In addition, there also was a recommendation to limit the work of all commercial offices and nongovernmental organizations "in that perimeter, and local residents were warned of the increased threat,” said lawmaker Mykyta Poturaiev, who said it's not the first time such a threat has been received. Ukraine’s Main Intelligence Directorate said the Oreshnik missile was fired from the Kapustin Yar 4th Missile Test Range in Russia’s Astrakhan region and flew 15 minutes before striking Dnipro. Test launches of a similar missile were conducted in October 2023 and June 2024, the directorate said. The Pentagon confirmed the missile was a new, experimental type of intermediate-range missile based on its RS-26 Rubezh intercontinental ballistic missile. Thursday's attack struck the Pivdenmash plant that built ICBMs when Ukraine was part of the Soviet Union. The military facility is located about 4 miles southwest of the center of Dnipro, a city of about 1 million that is Ukraine’s fourth-largest and a key hub for military supplies and humanitarian aid, and is home to one of the country’s largest hospitals for treating wounded soldiers from the front before their transfer to Kyiv or abroad. We're all going to die someday. Still, how it happens—and when—can point to a historical moment defined by the scientific advancements and public health programs available at the time to contain disease and prevent accidents. In the early 1900s, America's efforts to improve sanitation, hygiene, and routine vaccinations were still in their infancy. Maternal and infant mortality rates were high, as were contagious diseases that spread between people and animals. Combined with the devastation of two World Wars—and the Spanish Flu pandemic in between—the leading causes of death changed significantly after this period. So, too, did the way we diagnose and control the spread of disease. Starting with reforms as part of Roosevelt's New Deal in the 1930s, massive-scale, federal interventions in the U.S. eventually helped stave off disease transmission. It took comprehensive government programs and the establishment of state and local health agencies to educate the public on preventing disease transmission. Seemingly simple behavioral shifts, such as handwashing, were critical in thwarting the spread of germs, much like discoveries in medicine, such as vaccines, and increased access to deliver them across geographies. Over the course of the 20th century, life expectancy increased by 56% and is estimated to keep increasing slightly, according to an annual summary of vital statistics published by the American Academy of Pediatrics in 2000. Death Records examined data from the Centers for Disease Control and Prevention to see how the leading causes of death in America have evolved over time and to pinpoint how some major mortality trends have dropped off. According to a report published in the journal Annual Review of Public Health in 2000, pneumonia was the leading cause of death in the early 1900s, accounting for nearly 1 in 4 deaths. By the time World War I ended in 1918, during which people and animals were housed together for long periods, a new virus emerged: the Spanish Flu. Originating in a bird before spreading to humans, the virus killed 10 times as many Americans as the war. Many died of secondary pneumonia after the initial infection. Pneumonia deaths eventually plummeted throughout the century, partly prevented by increased flu vaccine uptake rates in high-risk groups, particularly older people. Per the CDC, tuberculosis was a close second leading cause of death, killing 194 of every 10,000 people in 1900, mainly concentrated in dense urban areas where the infection could more easily spread. Eventually, public health interventions led to drastic declines in mortality from the disease, such as public education, reducing crowded housing, quarantining people with active disease, improving hygiene, and using antibiotics. Once the death rates lagged, so did the public health infrastructure built to control the disease, leading to a resurgence in the mid-1980s. Diarrhea was the third leading cause of death in 1900, surging every summer among children before the impacts of the pathogen died out in 1930. Adopting water filtration, better nutrition, and improved refrigeration were all associated with its decline. In the 1940s and 1950s, polio outbreaks killed or paralyzed upward of half a million people worldwide every year. Even at its peak, polio wasn't a leading cause of death, it was a much-feared one, particularly among parents of young children, some of whom kept them from crowded public places and interacting with other children. By 1955, when Jonah Salk discovered the polio vaccine, the U.S. had ended the "golden age of medicine." During this period, the causes of mortality shifted dramatically as scientists worldwide began to collaborate on infectious disease control, surgical techniques, vaccines, and other drugs. From the 1950s onward, once quick-spreading deadly contagions weren't prematurely killing American residents en masse, scientists also began to understand better how to diagnose and treat these diseases. As a result, Americans were living longer lives and instead succumbing to noncommunicable diseases, or NCDs. The risk of chronic diseases increased with age and, in some cases, was exacerbated by unhealthy lifestyles. Cancer and heart disease shot up across the century, increasing 90-fold from 1900 to 1998, according to CDC data. Following the post-Spanish Flu years, heart disease killed more Americans than any other cause, peaking in the 1960s and contributing to 1 in 3 deaths. Cigarette smoking rates peaked at the same time, a major risk factor for heart disease. Obesity rates also rose, creating another risk factor for heart disease and many types of cancers. This coincides with the introduction of ultra-processed foods into diets, which plays a more significant role in larger waistlines than the increasing predominance of sedentary work and lifestyles. In the early 1970s, deaths from heart disease began to fall as more Americans prevented and managed their risk factors, like quitting smoking or taking blood pressure medicine. However, the disease remains the biggest killer of Americans. Cancer remains the second leading cause of death and rates still indicate an upward trajectory over time. Only a few types of cancer are detected early by screening, and some treatments for aggressive cancers like glioblastoma—the most common type of brain cancer—have also stalled, unable to improve prognosis much over time. In recent years, early-onset cancers, those diagnosed before age 50 or sometimes even earlier, have seen a drastic rise among younger Americans. While highly processed foods and sedentary lifestyles may contribute to rising rates, a spike in cancer rates among otherwise healthy young individuals has baffled some medical professionals. This follows the COVID-19 pandemic that began in 2020. At its peak, high transmission rates made the virus the third leading cause of death in America. It's often compared to the Spanish Flu of 1918, though COVID-19 had a far larger global impact, spurring international collaborations among scientists who developed a vaccine in an unprecedented time. Public policy around issues of safety and access also influences causes of death, particularly—and tragically—among young Americans. Gun control measures in the U.S. are far less stringent than in peer nations; compared to other nations, however, the U.S. leads in gun violence. Firearms are the leading cause of death for children and teens (around 2 in 3 are homicides, and 1 in 3 are suicides), and deaths from opioids remain a leading cause of death among younger people. Globally, the leading causes of death mirror differences in social and geographic factors. NCDs are primarily associated with socio-economic status and comprise 7 out of 10 leading causes of death, 85% of those occurring in low- and middle-income countries, according to the World Health Organization. However, one of the best health measures is life expectancy at birth. People in the U.S. have been living longer lives since 2000, except for a slight dip in longevity due to COVID-19. According to the most recent CDC estimates, Americans' life expectancy is 77.5 years on average and is expected to increase slightly in the coming decades. Story editing by Alizah Salario. Additional editing by Kelly Glass. Copy editing by Paris Close. Photo selection by Lacy Kerrick. This story originally appeared on Death Records and was produced and distributed in partnership with Stacker Studio. Be the first to know Get local news delivered to your inbox!Doordash director Tang Stanley sells $315k in stock

Ghana: CJID, DUBAWA harp on credible polls

Three long days of counting in the General Election finished late on Monday night when the final two seats were declared in the constituency of Cavan-Monaghan. Fianna Fail was the clear winner of the election, securing 48 of the Dail parliament’s 174 seats. Sinn Fein took 39 and Fine Gael 38. Labour and the Social Democrats both won 11 seats; People Before Profit-Solidarity took three; Aontu secured two; and the Green Party retained only one of its 12 seats. Independents and others accounted for 21 seats. The return of a Fianna Fail/Fine Gael-led coalition is now highly likely. However, their combined seat total of 86 leaves them just short of the 88 needed for a majority in the Dail. While the two centrist parties that have dominated Irish politics for a century could look to strike a deal with one of the Dail’s smaller centre-left parties, such as the Social Democrats or Labour, a more straightforward route to a majority could be achieved by securing the support of several independent TDs. For Fianna Fail leader Micheal Martin and current taoiseach and Fine Gael leader Simon Harris, wooing like-minded independents would be likely to involve fewer policy concessions, and financial commitments, than would be required to convince another party to join the government benches. Longford-Westmeath independent TD Kevin “Boxer” Moran, who served in a Fine Gael-led minority government between 2017 and 2020, expressed his willingness to listen to offers to join the new coalition in Dublin. “Look, my door’s open,” he told RTE. “Someone knocks, I’m always there to open it.” Marian Harkin, an independent TD for Sligo-Leitrim, expressed her desire to participate in government as she noted that Fianna Fail and Fine Gael were within “shouting distance” of an overall majority. “That means they will be looking for support, and I certainly will be one of those people who will be speaking to them and talking to them and negotiating with them, and I’m looking forward to doing that, because that was the reason that I ran in the first place,” she said. Meanwhile, the Social Democrats and Irish Labour Party both appear cautious about the prospect of an alliance with Fianna Fail and Fine Gael. They will no doubt be mindful of the experience of the Green Party, the junior partner in the last mandate. The Greens experienced near wipeout in the election, retaining only one of their 12 seats. Sinn Fein appears to currently have no realistic route to government, given Fianna Fail and Fine Gael’s ongoing refusal to share power with the party. Despite the odds being stacked against her party, Sinn Fein president Mary Lou McDonald contacted the leaders of the Social Democrats and Labour on Monday to discuss options. Earlier, Fianna Fail deputy leader and outgoing Finance Minister Jack Chambers predicted that a new coalition government would not be in place before Christmas. Mr Chambers said planned talks about forming an administration required “time and space” to ensure that any new government will be “coherent and stable”. After an inconclusive outcome to the 2020 election, it took five months for Fianna Fail, Fine Gael and the Greens to strike the last coalition deal. Mr Chambers said he did not believe it would take that long this time, as he noted the Covid-19 pandemic was a factor in 2020, but he also made clear it would not be a swift process. He said he agreed with analysis that there was no prospect of a deal before Christmas. “I don’t expect a government to be formed in mid-December, when the Dail is due to meet on December 18, probably a Ceann Comhairle (speaker) can be elected, and there’ll have to be time and space taken to make sure we can form a coherent, stable government,” he told RTE. “I don’t think it should take five months like it did the last time – Covid obviously complicated that. But I think all political parties need to take the time to see what’s possible and try and form a stable government for the Irish people.” Fine Gael minister of state Peter Burke said members of his parliamentary party would have to meet to consider their options before giving Mr Harris a mandate to negotiate a new programme for government with Fianna Fail. “It’s important that we have a strong, stable, viable government, whatever form that may be, to ensure that we can meet the challenges of our society, meet the challenges in terms of the economic changes that are potentially going to happen,” he told RTE. Despite being set to emerge with the most seats, it has not been all good news for Fianna Fail. The party’s outgoing Health Minister Stephen Donnelly became one of the biggest casualties of the election when he lost his seat in Wicklow in the early hours of Monday morning. Mr Donnelly was always predicted to face a fight in the constituency after boundary changes saw it reduced from five to four seats. If it is to be a reprise of the Fianna Fail/Fine Gael governing partnership of the last mandate, one of the major questions is around the position of taoiseach and whether the parties will once again take turns to hold the Irish premiership during the lifetime of the new government. The outcome in 2020 saw the parties enter a coalition on the basis that the holder of the premier position would be exchanged midway through the term. Fianna Fail leader Mr Martin took the role for the first half of the mandate, with Leo Varadkar taking over in December 2022. Current Fine Gael leader Mr Harris succeeded Mr Varadkar as taoiseach when he resigned from the role earlier this year. However, this time Fianna Fail has significantly increased its seat lead over Fine Gael, compared with the last election when there were only three seats between the parties. The size of the disparity in party numbers is likely to draw focus on the rotating taoiseach arrangement, raising questions as to whether it will be re-run in the next coalition and, if it is, on what terms. On Sunday, Simon Coveney, a former deputy leader of Fine Gael, said a coalition that did not repeat the rotating taoiseach arrangement in some fashion would be a “difficult proposition” for his party. Meanwhile, Fine Gael minister Paschal Donohoe said he would be making the case for Mr Harris to have another opportunity to serve as taoiseach. On Monday, Mr Chambers said while his party would expect to lead the government it would approach the issue of rotating the taoiseach’s role on the basis of “mutual respect” with Fine Gael. “I think the context of discussions and negotiations will be driven by mutual respect, and that’s the glue that will drive a programme for government and that’s the context in which we’ll engage,” he said. On Monday, Labour leader Ivana Bacik reiterated her party’s determination to forge an alliance with fellow centre-left parties with the intention of having a unified approach to the prospect of entering government. Asked if Labour was prepared to go into government with Fianna Fail and Fine Gael on its own, she told RTE: “No, not at this stage. We are absolutely not willing to do that. “We want to ensure there’s the largest number of TDs who share our vision and our values who want to deliver change on the same basis that we do.” The Social Democrats have been non-committal about any potential arrangement with Fianna Fail and Fine Gael, and have restated a series of red lines they would need to achieve before considering taking a place in government. Leader Holly Cairns, who gave birth to a daughter on polling day on Friday, said in a statement: “The party is in a very strong position to play an important role in the next Dail. In what position, government or opposition, remains to be seen.” Fianna Fail secured the most first preference votes in Friday’s proportional representation election, taking 21.9% to Fine Gael’s 20.8%. Sinn Fein came in third on 19%. While Sinn Fein’s vote share represented a marked improvement on its disappointing showing in June’s local elections in Ireland, it is still significantly down on the 24.5% poll-topping share it secured in the 2020 general election. The final breakdown of first preferences also flipped the result of Friday night’s exit poll, which suggested Sinn Fein was in front on 21.1%, with Fine Gael on 21% and Fianna Fail on 19.5%.Need a Year-End Photobook? I Tried Mixbook's AI Tool

AP Trending SummaryBrief at 4:17 p.m. EST

IT couple Kyline Alcantara and Kobe Paras find the ‘REAL DEAL’ on ZALORA this 12.12Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

In Chongqing, China, TECNO introduced three advanced imaging technologies that promise to reshape the landscape of everyday smartphone photography. Rather than focusing on features that only professionals or enthusiasts can navigate, The company has set its sights on making advanced imaging accessible to anyone with a mobile device from TECNO. By showcasing TECNO Image Matrix (TIM), EVS Dynamic Snapshot, and Tap Any Zoom Dual Prism Telephoto at Future Lens 2024, the company emphasized that crisp, lifelike images and smooth shooting experiences can be the norm, not the exception. Designer: TECNO This ambition reflects TECNO’s guiding principle of “Stop At Nothing,” a philosophy that rejects the notion of accepting limitations as inevitable. Instead of working around constraints like poor lighting or distant subjects, TECNO strives to eliminate them. In doing so, the brand stands by its mission to uplift emerging markets and ensure that even users who have historically been overlooked can share in the benefits of cutting-edge imaging technology. This approach goes hand-in-hand with a broader AI Vision strategy. As Huang Xiao Han, Director of TECNO’s Image R&D Center, explains, the company is committed to “leveraging new AI technologies alongside advanced imaging technologies to deliver even better imaging experiences for users.” In other words, TECNO’s progress focuses on everyday improvements but represents a continuous effort to redefine what mobile cameras can achieve. The outcome of these efforts represents a significant technical upgrade. By developing imaging systems that adapt to real-world conditions, TECNO empowers individuals to document their lives with clarity and emotion. Through thoughtful design and consistent effort, the brand works to ensure that people around the world can capture the images that matter most, free from the frustrations that once seemed unavoidable. TECNO Image Matrix, commonly known as TIM, transforms how a smartphone handles visual data. Many devices stumble under the pressure of running multiple AI imaging tasks simultaneously, resulting in slower performance and reduced quality. TIM confronts this issue by rearranging the data pipeline so that each step, from initial capture to final output, receives the optimal level of computing power. Rather than making the user wrestle with settings, TIM does the heavy lifting behind the scenes, ensuring that complexity never spills over into the shooting experience. At its core, TIM depends on a solid hardware foundation—sensors, camera modules, and display components harmonize to create a stable base. Above this, a series of refinements eliminates noise, balances colors, and enhances stability before the image data reaches TIM’s central hub, known as TAPS (TECNO Algorithm Process Stack). Here, four specialized AI engines work in concert—AI RAW, AI SNAP, AIGC Studio, and AI UT. AI RAW sharpens low-light and backlit scenes, AI SNAP removes shutter lag, AIGC Studio opens doors for creative enhancement and editing, and AI UT restores natural skin tones. Each engine addresses a long-standing pain point, turning once-complicated challenges into frictionless experiences. The beauty of TIM is that it shields users from the technical intricacies at play beneath the surface. One no longer needs to understand advanced photography principles to produce images that are sharp, vibrant, and true to life. The camera intuitively reacts to the environment, ensuring that even in tricky situations—dim alleys, high-contrast street scenes, or fleeting personal moments—the user emerges with a photograph that feels effortless and complete. Capturing a subject in motion has long been a gamble for smartphone photographers. Time the shot too early or too late, the moment disappears into a blur. Traditional cameras operate frame-by-frame, forcing users to hope their reflexes align with the perfect instant. More often than not, the result is a smeared record of action rather than a crisp reflection of what actually transpired. EVS Dynamic Snapshot reframes how motion is recorded and represented. Instead of merely grabbing a split-second, it tracks the subject’s entire path of movement, converting continuous motion into rich data. Intelligent AI algorithms then merge this dynamic information with the stable background captured by the RGB camera. The outcome is a single, clear image that conveys the energy and vitality of the scene. Whether it is a child’s carefree twirl, an athlete’s decisive leap, or a bird’s graceful flight, the camera now captures the position and essence of that kinetic event. For everyday users, EVS Dynamic Snapshot dramatically reduces the anxiety around action shots. No longer does one need to guess when to press the shutter. The technology ensures the camera can handle motion on its own terms, delivering naturally sharp and full-of-life results. For motorsport journalists and photographers like myself, capturing a speeding F1 car on a track isn’t the easiest. This is one area of digital photography in which I’m eager to test this technology in the future. Beyond the professional field, EVS Dynamic Snapshot also promises to capture everyday moments that might otherwise be lost to motion blur. This technology bridges the gap between dynamic scenes and the clarity needed to preserve them effectively, from children’s sports events to lively city streets. Instead of missing or distorting these special moments, users are free to enjoy them, confident that their phone will preserve them in all their clarity. Distant subjects have traditionally posed another set of challenges. Zooming in often produces shaky images that fail to do justice to the beauty of far-off scenes. Without a steady hand or additional equipment, capturing a distant monument’s intricate details or a stunning panorama can feel out of reach. The telephoto function becomes an exercise in patience and compromise. Tap Any Zoom Dual Prism Telephoto dismantles these barriers by blending a dual prism design with lens-shift optical stabilization and AI-driven decision-making. Instead of fumbling with pinch gestures or hoping your hand remains steady, a double tap on the desired subject instantly sets the ideal zoom. The dual prism configuration grants a wide field for stabilization, while AI calculations and lens-shift corrections neutralize tremors and external vibrations. This seamless interplay ensures that the image remains crisp and stable even at significant magnifications. By simplifying the once-difficult process of long-range photography, Tap Any Zoom Dual Prism Telephoto invites users to capture scenes that would otherwise remain elusive. A sweeping mountain range, a distant architectural marvel, or subtle wildlife activity can now be preserved with remarkable clarity. Instead of grudgingly accepting the limits of smartphone zoom, users discover a new layer of freedom and creative possibility. The trio of innovations—TECNO Image Matrix, EVS Dynamic Snapshot, and Tap Any Zoom Dual Prism Telephoto—represents a holistic rethinking of the camera’s role in daily life. Each addresses a longstanding frustration that once required skill, patience, or sheer luck to overcome. Together, they deliver a camera experience that aligns with a person’s natural instincts rather than forcing them to adapt to technical shortcomings. For everyday users, this means that the shift from an afternoon stroll to a gallery-worthy photograph no longer hinges on trial and error. Nighttime portraits lose their murkiness, action sequences gain definition, and distant scenes reveal themselves without compromise. The AIGC Studio engine encourages users to personalize their images, adding their own touch without becoming bogged down in intricate editing software. The camera, in effect, becomes a medium through which individual perspectives come to life. These improvements don’t eliminate every trade-off. More advanced AI functions may consume additional processing power or demand a short period of adjustment. Yet the gains—greater flexibility, improved quality, and effortless operation—far outweigh these considerations. By reducing barriers and expanding its creative range, TECNO empowers users of all skill levels to capture their environments with authenticity and nuance. The Future Lens 2024 event in Chongqing highlighted TECNO’s determination to continually break new ground. Rather than accepting the old standard where cameras struggled with low-light scenes, rapid motion, or distant targets, the company pursued a different outcome. The Stop At Nothing mantra means that every challenge is merely an opportunity to innovate further. It’s a pledge to keep refining the user experience, fueled by an AI Vision strategy that, as Huang Xiao Han stated, aims to leverage emerging technologies to elevate imaging for everyone. As these advances evolve, I look forward to Mobile World Congress 2025 for more specifics on how and when these features will filter into mainstream devices. The conversation doesn’t end with this event; it continues as TECNO refines its approach, delivering smarter and more versatile cameras with each iteration. By staying true to its philosophy, the company ensures that innovation never remains an abstract ideal but becomes a tangible reality in the hands of its users. Ultimately, the technologies introduced at Future Lens 2024 point to a world where the camera’s capabilities are no longer defined by limitations but by how well it can adapt and excel. Every subtle shade in a dim alley, every fleeting smile caught in motion, and every distant marvel transformed into a masterpiece become attainable. This is the future TECNO envisions: one shaped by intelligence, guided by user needs, and anchored by a promise to stop at nothing in the quest to deliver extraordinary imaging experiences.